These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 23642023)

  • 21. Allosteric ligands for the corticotropin releasing factor type 1 receptor modulate conformational states involved in receptor activation.
    Hoare SR; Fleck BA; Gross RS; Crowe PD; Williams JP; Grigoriadis DE
    Mol Pharmacol; 2008 May; 73(5):1371-80. PubMed ID: 18239030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural-functional analysis of the third transmembrane domain of the corticotropin-releasing factor type 1 receptor: role in activation and allosteric antagonism.
    Spyridaki K; Matsoukas MT; Cordomi A; Gkountelias K; Papadokostaki M; Mavromoustakos T; Logothetis DE; Margioris AN; Pardo L; Liapakis G
    J Biol Chem; 2014 Jul; 289(27):18966-77. PubMed ID: 24838244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential regulation of gonadotropin-releasing hormone by corticotropin-releasing factor family peptides in hypothalamic N39 cells.
    Kageyama K; Hasegawa G; Akimoto K; Yamagata S; Tamasawa N; Suda T
    Peptides; 2012 Jan; 33(1):149-55. PubMed ID: 22138165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
    Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
    Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The design, synthesis and structure-activity relationships of 1-aryl-4-aminoalkylisoquinolines: a novel series of CRF-1 receptor antagonists.
    Yoon T; De Lombaert S; Brodbeck R; Gulianello M; Chandrasekhar J; Horvath RF; Ge P; Kershaw MT; Krause JE; Kehne J; Hoffman D; Doller D; Hodgetts KJ
    Bioorg Med Chem Lett; 2008 Feb; 18(3):891-6. PubMed ID: 18180159
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in small molecule antagonists of the corticotropin-releasing factor type-1 receptor-focus on pharmacology and pharmacokinetics.
    Chen C
    Curr Med Chem; 2006; 13(11):1261-82. PubMed ID: 16712469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models.
    Kehne JH; Cain CK
    Pharmacol Ther; 2010 Dec; 128(3):460-87. PubMed ID: 20826181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The CRF1 receptor, a novel target for the treatment of depression, anxiety, and stress-related disorders.
    Kehne JH
    CNS Neurol Disord Drug Targets; 2007 Jun; 6(3):163-82. PubMed ID: 17511614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-activity studies on the corticotropin releasing factor antagonist astressin, leading to a minimal sequence necessary for antagonistic activity.
    Rijkers DT; Kruijtzer JA; van Oostenbrugge M; Ronken E; den Hartog JA; Liskamp RM
    Chembiochem; 2004 Mar; 5(3):340-8. PubMed ID: 14997526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allosteric antagonist binding sites in class B GPCRs: corticotropin receptor 1.
    Bhattacharya S; Subramanian G; Hall S; Lin J; Laoui A; Vaidehi N
    J Comput Aided Mol Des; 2010 Aug; 24(8):659-74. PubMed ID: 20512399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel substituted tetrahydrotriazaacenaphthylene derivatives as potent CRF1 receptor antagonists.
    Gentile G; Di Fabio R; Pavone F; Sabbatini FM; St-Denis Y; Zampori MG; Vitulli G; Worby A
    Bioorg Med Chem Lett; 2007 Sep; 17(18):5218-21. PubMed ID: 17629700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
    Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
    J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonists.
    Gilligan PJ; He L; Clarke T; Tivitmahaisoon P; Lelas S; Li YW; Heman K; Fitzgerald L; Miller K; Zhang G; Marshall A; Krause C; McElroy J; Ward K; Shen H; Wong H; Grossman S; Nemeth G; Zaczek R; Arneric SP; Hartig P; Robertson DW; Trainor G
    J Med Chem; 2009 May; 52(9):3073-83. PubMed ID: 19361210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CRH-sub-1 receptor antagonists for the treatment of depression and anxiety.
    Ising M; Holsboer F
    Exp Clin Psychopharmacol; 2007 Dec; 15(6):519-28. PubMed ID: 18179304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N-phenylphenylglycines as novel corticotropin releasing factor receptor antagonists.
    Molteni V; Penzotti J; Wilson DM; Termin AP; Mao L; Crane CM; Hassman F; Wang T; Wong H; Miller KJ; Grossman S; Grootenhuis PD
    J Med Chem; 2004 May; 47(10):2426-9. PubMed ID: 15115386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists.
    Gross RS; Guo Z; Dyck B; Coon T; Huang CQ; Lowe RF; Marinkovic D; Moorjani M; Nelson J; Zamani-Kord S; Grigoriadis DE; Hoare SR; Crowe PD; Bu JH; Haddach M; McCarthy J; Saunders J; Sullivan R; Chen T; Williams JP
    J Med Chem; 2005 Sep; 48(18):5780-93. PubMed ID: 16134945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression.
    Alonso R; Griebel G; Pavone G; Stemmelin J; Le Fur G; Soubrié P
    Mol Psychiatry; 2004 Mar; 9(3):278-86, 224. PubMed ID: 14699428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of CRF receptor signaling in stress vulnerability, anxiety, and depression.
    Hauger RL; Risbrough V; Oakley RH; Olivares-Reyes JA; Dautzenberg FM
    Ann N Y Acad Sci; 2009 Oct; 1179():120-43. PubMed ID: 19906236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Corticotropin-releasing factor receptor 1 mediates acute and delayed stress-induced visceral hyperalgesia in maternally separated Long-Evans rats.
    Schwetz I; McRoberts JA; Coutinho SV; Bradesi S; Gale G; Fanselow M; Million M; Ohning G; Taché Y; Plotsky PM; Mayer EA
    Am J Physiol Gastrointest Liver Physiol; 2005 Oct; 289(4):G704-12. PubMed ID: 15994424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-peptide CRF-Receptor Antagonists: Allosterism, Kinetics and Translation to Efficacy in Human Disease.
    Hoare SRJ; Grigoriadis DE
    Curr Mol Pharmacol; 2017; 10(4):282-295. PubMed ID: 28103785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.